Literature DB >> 2462876

An analysis of the inhibition of replication of HIV and MuLV by some 3'-blocked pyrimidine analogs.

H Bazin1, J Chattopadhyaya, R Datema, A C Ericson, G Gilljam, N G Johansson, J Hansen, R Koshida, K Moelling, B Oberg.   

Abstract

Some 3'-blocked pyrimidine analogs were synthesized and tested as inhibitors of replication of human immunodeficiency virus (HIV) and Moloney-murine leukemia virus (MuLV). The analogs were of 3 kinds: (1) analogs of 3'-azido-3'-deoxythymidine (AZT) in which the C-5 CH3 of the base was exchanged for H (AZU) or C2H5 (AZEU); (2) 3'-fluoro-3'-deoxythymidine (FLT) and analogs thereof, in which the C-5 CH3 of the base was exchanged for H (FLU), C2H5 (FLEU) or nC3H7 (FLPU); (3) the threo analogs of AZT (AZT increases) and AZU (AZU increases). All analogs were less active inhibitors of HIV replication than AZT, except FLT, which was as active as AZT. The 3'-fluoro analogs and AZEU did not inhibit MuLV replication at non-cytotoxic concentrations. Oral administration of FLT to MuLV-infected mice result in antiviral effects only at toxic drug levels. AZU and FLU were less potent inhibitors of HIV replication than AZT or FLT, but the 2'-deoxy uridine analogs were less cytotoxic to human embryonic fibroblasts than the thymidine analogs. The 5'-triphosphates of AZU, AZT, AZEU, FLT and FLEU were tested as inhibitors of the HIV- and MuLV-reverse transcriptases. Ranking of the Ki/Km values for HIV-RT resulted in the following order of potency of the 5'-triphosphates AZT = FLT greater than AZU greater than AZEU greater than FLEU. The 5'-triphosphates of AZEU, FLT and FLEU did not inhibit the MuLV-RT, which explains, in part, the lack of effect of these analogs against MuLV replication. The threo forms (azido "up") of AZU and AZT were less active inhibitors of HIV replication than the erythro forms (azido "down"). A 15N-NMR and 1H-NMR study showed that the furanose moieties of analogs with the azido function "up" assume a conformation distinct from that of the analogs with azido "down". This is due to intramolecular stabilisation of the "N" conformer in the threo ("up") diastereomer, due to interaction of the azido functions with the nucleobase and possibly the OH group of C-5' of the furanose. As discussed, this conformation might explain the decreased biological activity of threo forms compared with the erythro forms.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2462876     DOI: 10.1016/0006-2952(89)90157-3

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  Screening for new agents.

Authors:  B Oberg; L Vrang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-07       Impact factor: 3.267

2.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats.

Authors:  F D Boudinot; S G Smith; E D Funderburg; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Comparison of in vitro biological properties and mouse toxicities of three thymidine analogs active against human immunodeficiency virus.

Authors:  M M Mansuri; M J Hitchcock; R A Buroker; C L Bregman; I Ghazzouli; J V Desiderio; J E Starrett; R Z Sterzycki; J C Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

4.  Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1.

Authors:  R Koshida; S Cox; J Harmenberg; G Gilljam; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

5.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.

Authors:  R F Schinazi; F D Boudinot; K J Doshi; H M McClure
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 6.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 7.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Penetration of zidovudine and 3'-fluoro-3'-deoxythymidine into the brain, muscle tissue, and veins in cynomolgus monkeys: relation to antiviral action.

Authors:  E Ljungdahl-Ståhle; E Guzenda; D Böttiger; B Wahren; B Oberg; L Ståhle
Journal:  Antimicrob Agents Chemother       Date:  1992-11       Impact factor: 5.191

9.  Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine.

Authors:  X B Kong; Q Y Zhu; P M Vidal; K A Watanabe; B Polsky; D Armstrong; M Ostrander; S A Lang; E Muchmore; T C Chou
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

Review 10.  Antiviral therapy in human immunodeficiency virus infection.

Authors:  E Sandström
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.